Kaynak: CNBC
Haber Ajansı
Hisse Senedi
Orta Önem
Novo Nordisk's raised forecast fails to change the debate over its obesity business
Novo Nordisk raised its full year outlook late Tuesday. Analysts said the better-than-expected quarter benefited from rebate adjustments and other temporary factors, while obesity drug sales were largely in line with expectations and oral Wegovy slightly missed forecasts.
İlgili Semboller
1
N
NVO
NVO
Kaynak: CNBC
Kaynağı Ziyaret Et